_edited.png)
RISK CONCERN
Investment Strategy, Risk Analysis, and Insights by Chartered Professionals
SRDX
Primary Facts
Medical Devices
Name:
-
Sector:
- 7026.00K
Industry:
31.25
CEO:
Mr. Gary Maharaj
Total Employees:
Small Cap
Our Technological Advancement Rating
Our Rating:
2.826658659
13.52527255
Surmodics, Inc. (XNAS:SRDX) In-Depth Stock/Fundamental/Options Analysis Today
Primary Targets/Price Insights
Previous Close ($) :
Surmodics, Inc. (XNAS:SRDX)
One Month Price Target:
Six Month Price Target :
$31.42
Likely Price in One Year's Time:
Ticker:
$32.25
Likely Trading Range Today Under (Normal Volatility)
$31.41
Price Upper limit ($) :
$33.25
Price Lower limit ($) :
Crash Risk Prep/Key Price Levels (High Volatility/Risk)
Price, as per data analysis, isn't likely to fall below:
Today:
P354
This week:
$29.39
This month :
$27.1
Other Primary facts
Market Cap:
14.01M
Market Cap Classification:
429.39M
Number of Shares
IPO Date:
D
Best/Worst Daily Performance (Last 3+ Years)
Highest Daily Appreciation:
-13.71%
$22.95
Worst Daily Decline:
Our Options Trading Entry Points
Iron Condor entry points for options expiring in 1 week's time
Low risk (<2%) entry points
Buy Call:
Sell Call:
Buy Put:
Sell Put:
$35.94
21.03%
$26.56
$39.87
Medium risk (<10%) entry points
Buy Call
Sell Call
$33.83
Buy Put:
Sell Put:
$22.63
$28.67
$34.67
These entry points can be used for other strategies, such as butterflies, straddles, etc.
Risk-Adjusted returns (Sharpe Ratio) of
Medical Devices
Sharpe Ratio:
SRDX, is amongst the top 40% lowest yielding stocks in terms of daily returns
Comparison:
1.51%
-1.015139867
Sharpe ratio is -101.51% lower than the industry
Average Returns/Yield of
Medical Devices
Daily returns:
1
Weekly returns:
0.01%
Monthly returns:
0.04%
Yearly returns:
1.96%
Comparison of returns:
-0.87210044
Classification:
Average annual returns/yield (last 3 years) is -87.21% below industry average
Results of T-Test of Returns:
SRDX is a riskier investment compared to Nasdaq (IXIC)
Statistical test of Returns:
0.65
Volatility (measured by Standard Deviation)
Daily Volatility:
& is -101.01% lower than the market/S&P 500 average
Weekly Volatility:
2.90%
Monthly Volatility:
6.47%
Yearly Volatility:
12.95%
Volitlilty of last five days (Measured by Standard Deviation)
Average Volatility of this Week:
56.44%
-6.48%
Value at Risk Analysis (VaR)
Daily VaR:
Volatility in last five trading days has been -6.48% below long-term volatility
Weekly VaR:
-5.94%
Monthly VaR:
-13.28%
How Much Can the price of
Medical Devices
Decline in a Recession?
Likely price decline in a recession:
Base case (decline):
Risk of crash in next 6/12 months: Low (<25%)
Worst case (decline):
$23.94
This translates to price declining to:
-23%
This translates to price declining to:
-91.99%
Severe Crash Probability
-26.56%
What is Value at Risk (VaR)?
Risk Fundamentals
60.57%
SRDX is a 87.43% riskier investment compared to the market/S&P 500 & is 60.57% riskier than Nasdaq (IXIC)
SRDX is a 87.43% riskier investment compared to the market/S&P 500
Beta Examination of
Medical Devices
0.953
Expected beta in 1 year's time:
0.749
Expected beta in 3 year's time:
0.63
Unlevered (debt free) Beta:
Beta in relation to market/S&P 500--0.95
Beta in relation to Nasdaq (XNAS):
Returns are right (positive) skewed; mean returns are greater than median and mode returns
Beta in relation to all global stocks::
Beta is -10.51% below industry average
Beta Comparison & Analysis
Beta of competitors/peers::
0.7
-0.177
Average Industry Beta:
Beta is -17.67% lower than peers
-0.105107461
Sustainable Growth Rate Analysis
Sustainable growth rate for this stock/firm:
WACC is 19.70% above industry mean WACC
-90.68%
Alpha provided | Alpha Analysis
Alpha provided:
0.891
-2.570
-4.910
Analysis of Cost of Capital of
Medical Devices
Equity cost of capital:
Alpha is -491% below the market average
-0.073
Unlevered (without debt) cost of capital:
Equity cost of capital is -7.34% below industry mean WACC
Before-tax cost of debt:
7.11%
After-tax cost of debt:
3.20%
Overall debt rating:
2.53%
Weighted average cost of capital (WACC):
3.20%
19.70%
Key Per-Share Metrics & Analysis
Revenue per share:
-
Revenue growth rate per share of (3Y):
Price to sales ratio is -51.51% below the industry mean
-93.68%
EPS:
-
Expected Annual growth rate of EPS (3Y):
-
-449.82%
Free cash flow (FCF) per share:
Price to book ratio is -62.65% below the industry mean
Growth rate in R&D investment/expenditure is 76162.05% higher than the industry
-
Debt per share
Debt repayment rate in last quarter: 100.00%
EBITDA per share
Each employee generates -138% less EBITDA than industry average revenue per employee
Valuation Analysis Today of
Medical Devices
P/E Ratio:
Sustainable growth rate is -90.68% below industry average
P/E Ratio of Competitors/Peers:
344.1
0.41286174
-182.659115
-1.171083715
-
-
P/S (Price to Sales ratio):
$6.92
-0.515056248
P/B (Price to book value ratio):
Price to sales ratio is -51.51% below the industry mean
-
-
Net income growth rate (3Y):
Annual revenue growth rate is -93.68% below industry average
-296.51%
Dividend Analysis
Net income growth rate is -296.51% lower than the industry average net income growth rate
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Dividend History:
-
--$0.00
--$0.00
--$0.00
--$0.00
--$0.00
-
In-depth Debt & Leverage Analysis
Debt to equity ratio:
-12.18%
Net debt to equity ratio:
The remaining useful life of property plant & equipment is: 0.0 years
Debt to assets ratio:
-9.01%
Net debt to assets ratio:
35.26%
-32.71%
Ability to repay debt:
Interest coverage ratio:
Debt-to-asset ratio is -32.71% below industry average
-1.21
Looking forward:
Debt growth rate:
1.4x
1157.67%
100.00%
Analysis of Key Statistics
Correlation of price movement with the market:
10.43927961
Statistical significance of correlation:
-0.48%
Average Correlation of the industry with the market:
0.371
-20.72%
R Squared (percentage of price movement explained by movement of the market):
0.371
Correlation of price movement with Nasdaq (^IXIC):
0.137
Covariance of price movement with the market:
-0.045
Kurtosis
-0.076
8.044
Skewness of returns:
Returns have a significant fat-tails (leptokurtic), i.e., returns considerably higher or lower than the mean returns are more probable, compared to assets with normally distributed returns
0.628
Fundamental Analysis & Dupont Analysis of
Medical Devices
Gross Profit Margin Ratio:
41.40M
Operating Profit Margin Ratio:
Net profit margin is -36.75% lower than the industry
-32.26%
Net Profit Margin Ratio:
41.40M
Effective Tax Rate:
-16.04%
-1.045544674
Dupont Method
Net Profit Margin
Return on Equity Ratio (ROE):
×
ROA
=
×
Return on assets (ROA) is 68.01% higher than the industry
-21.86%
Financial Leverage
Asset Turnover Ratio (ROA):
Operating profit margin is -32.26% lower than the industry
68.01%
Financial Leverage:
Interest coverage ratio is -121.41% less than industry average
Current Ratio:
Return on equity (ROE) is -21.86% lower than the industry
-0.608408548
Cash Conversion Cycle (days):
$0.00
-0.480631937
Current ratio is -60.84% below industry average
Stock based compensation to net income ratio:
-
In-depth Efficiency Analysis
Revenue generated per employee:
Cash conversion cycle is -48.06% below industry average
-0.338696776
EBITDA generated per employee:
Each employee generates -34% less revenue than industry average revenue per employee
-1.375580827
Profit generated per employee:
-$0.07
-9%
Free cash flow (FCF) generated per employee:
Each employee generates -9% less net income/profit than industry average revenue per employee
0.271575476
Assets/Capital per employee
Each employee generates 27% more free cash flow than industry average revenue per employee
0.271575476
Research & Development (R&D) Analysis
-100.00%
761.6205056
Competitors/Peer firms of
Medical Devices
$42.75
BICYCLE THERAPEUTICS PLC (XNAS:BCYC)
ANNEXON, INC. (XNAS:ANNX)
THE JOINT CORP. (XNAS:JYNT)
Gracell Biotechnologies Inc (XNAS:GRCL)
SYNDAX PHARMACEUTICALS, INC. (XNAS:SNDX)
BIOXCEL THERAPEUTICS, INC. (XNAS:BTAI)
Prometheus Biosciences, Inc. (XNAS:RXDX)
Merus NV (XNAS:MRUS)
Current Analyst Ratings
-$0.75
Strong buy�0%
Buy�8%
Hold�8%
Sell�0%
Strong sell�0%
Income Statement
Period:
3/31/2022
Date:
Value
Revenue:
TTM
Cost of Revenue:
Gross Profit:
R&D Expense
General & Admin Expenses:
Selling, General & Admin Expenses
Sales and Marketing Expenses
Other Expenses :
Operating Expenses :
Cost & Expenses :
Interest Income:
Interest Expenses:
Depreciation & Amortization:
EBITDA:
Operating Income:
Other Income Expenses:
Income Before Tax:
Income Tax Expense:
Net Income:
Balance Sheet
Date:
Calendar Year:
Period:
Cash & Cash Equivalents:
Short Term Investments:
Cash & Short Term Investments:
Net Receivables:
Inventory:
Other Current Assets:
Total Current Assets:
PP&E:
Goodwill:
Intangible Assets:
Long Term Investments:
Tax Assets:
Other Non-Current Assets:
Total Non-Current Assets:
Other Assets:
Total Assets:
Accounts Payable:
Short Term Debt:
Tax Payables:
Deferred Revenue:
Other Current Liabilities:
Total Current Liabilities:
Long Term Debt:
Other Non-Current Liabilities:
Total Non Current Liabilities:
Other Liabilities:
Total Liabilities:
Common Stock:
Retained Earnings:
Accumulated Other Comprehensive Loss:
Other Total Stockholders' Equity:
Total Stockholders' Equity:
Total Liabilities and Stockholders' Equity:
Total Investments:
Total Debt:
Net Debt:
96.95M
55.56M
174%
2.56M
-
36.05M
-
17.44M
107.11M
-
320.00K
8.95M
-3%
290.00K
- 379.00K
-47%
290.00K
Statement of Cash Flow
Date:
Period:
- 2812.00K
Differed Income Tax :
2.38M
Stock Based Compensation :
- 640.00K
Change in Working Capital :
1.68M
Accounts Receivables:
- 7802.00K
Other Working Capital:
200.00K
Other Non-Cash Items:
- 1320.00K
Net Cash Provided by Operating Activities:
172.00K
Investments in PP&E:
- 7026.00K
Net Acquisitions:
- 782.00K
Purchases of Investments:
-
Sales/Maturities of Investments:
Other Investing Activities:
Net Cash Used for Investing Activities:
Debt Repayment:
Common Stock Issued:
Common Stock Repurchased:
Dividend Paid:
Other Financing Activities:
Net Cash Used Provided by Financing Activities:
Effect of FOREX on Changes in Cash:
Net Changes in Cash:
Cash at End of Period:
Cash at Beginning of Period:
Operating Cash Flow:
Capital Expenditure:
Free Cash Flow (FCF):
Value
12/31/2021
2022
Q1
26.65M
5.69M
32.34M
8.01M
8.29M
16.27M
64.92M
29.32M
44.90M
35.24M
-
6.37M
4.12M
119.95M
-
184.87M
1.85M
10.00M
1.92M
4.43M
9.37M
25.64M
-
10.71M
22.55M
-
48.20M
699.00K
113.25M
75.0K
Value
56.05M
136.67M
136.67M
184.87M
-
10.00M
-
4.00M
-
3.22M
3.00K
230.00K
-
-
- 856.00K
- 623.00K
- 72.00K
- 4503.00K
26.65M
31.15M
- 7026.00K
- 782.00K
Our Proprietary Portfolio Rating
Our Rating:
-94051.1379
Price Forecast/Expected Price in Next 5 Years of
Medical Devices
2023
2024
2025
2026
2027
33.354405
$33.35
$35.49
$37.76
$40.18